Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma - Annals of Oncology
ESMO E-Learning: Present and Emerging Treatment Options in HER2/NEU Overexpressing Metastatic Breast Cancer
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars | SpringerLink
What therapies are on the horizon for HER2 positive breast cancer?
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library
HER2 TKIs for CNS Disease - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
Cancers | Free Full-Text | Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature | HTML
Tucatinib | C26H24N8O2 - PubChem
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer - Mukohara - 2011 - Cancer Science - Wiley Online Library
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Frontiers | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients | Oncology
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance - ScienceDirect
Pipeline – Tucatinib (TUKYSA) – Seagen
HER2-targeted therapies — a role beyond breast cancer | Nature Reviews Clinical Oncology
Cancers | Free Full-Text | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | HTML
Management of HER2 Positive Metastatic Breast Cancer - ppt download
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models | Molecular Cancer Therapeutics
Resistance and Overcoming Resistance in Breast Cancer | BCTT
Evolution of anti-HER2 therapies for cancer treatment - ScienceDirect
ESMO E-Learning: Present and Emerging Treatment Options in HER2/NEU Overexpressing Metastatic Breast Cancer
Novel targeted therapies for metastatic breast cancer. - Abstract - Europe PMC
Evolution of anti-HER2 therapies for cancer treatment - Cancer Treatment Reviews
